Esohe Idusogie

Exploring the future of potency, where assays must mimic the tumor microenvironment and measure integrated functions beyond cytotoxicity. This panel will debate the practical limits of complexity, the role of surrogate assays, and how to validate a “systems biology” approach to potency.

Join a strategic discussion on building the agile ADC development organization of the future by:

• Debate how complex a potency assay should become to feasibly develop co-culture assays incorporating immune cells and stromal components to reflect the in vivo mechanism of action
• Explore the potential for non-cell-based binding assays, combined with AI models to serve as validated potency methods, reducing variability and resource strain while linking clinical efficacy
• Define the line between necessary scientific rigor and impractical method proliferation for dual-mechanism ADCs, to understand the minimum number of assays needed to ensure product quality

• Implement a single cell-killing assay where the combined effect is the primary driver of efficacy to simplify the control strategy and provide a direct measure of potency, streamlining development and validation for late-stage and commercial control
• Developing two orthogonal assays when it is critical to monitor each payload’s function independently, ensuring consistent quality and function of both therapeutic components
• Use mechanism-specific inhibitors or engineered resistant cell lines in bioassays to determne the contribution payload within a single assay, gaining deep product understanding without the resource burden of developing and validating separate methods